Clinical trials: Sacubitril/Valsartan
Heart Failure
Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis
This study intends to measure the effects of valsartan/sacubitril compared to baseline standard medical heart failure therapy on reverse remodeling using echocardiographic endocardial surface analysis techniques to assess changes…
- Trial name
- NCT02754518
- Testing
- Entresto
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Chicago
Heart Failure
Improvement of Left Ventricular Ejection Fraction in ICD Patients Undergoing Therapy With Sacubitril/Valsartan
The study is aimed to evaluate the improvement of the left ventricular volumes and of the left ventricular ejection fraction in a population of ICD patients with heart failure and left ventricle systolic dysfunction undergoing…
- Trial name
- SAVE-ICD (NCT03935087)
- Testing
- two-dimensional echocardiogram
- Where
- 6 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Azienda Ospedaliera Cardinale G. Panico
Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Secondary Use of PARALLEL-HF Data
This study utilized the blood and first morning void (FMV) urine samples from the PARALLEL-HF study (core part). The PARALLEL-HF study (core part) was a multicenter, randomized, double-blind, double-dummy, parallel-group…
- Trial name
- NCT07527767
- Where
- Japan
- Volunteers
- 236 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myocardial Infarction
The Role of Sacubitril/Valsartan in Post-acute Myocardial Infarction
Sacubitril/Valsartan (SAC/VAL) is a new treatment of congestive heart failure (CHF) recently indicated as class I, level of evidence B in the recent European Society of Cardiology (ESC) guidelines 2016 of CHF.
- Trial name
- RSVP-AMI (NCT03893435)
- Testing
- Sacubitril / Valsartan Oral Tablet [Entresto]
- Where
- Egypt
- Volunteers
- 192 people
- Sponsor
- The Young Investigator Group of Cardiovascular Research
Heart Failure
Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania
Angiotensin-neprilysin inhibitors (ARNI) are beneficial in patients with heart failure with reduced ejection fraction. No study evaluating ARNI has been conducted in sub-Saharan Africa (except South Africa) yet, where heart…
- Trial name
- NCT06704633
- Testing
- Sacubitril / Valsartan Oral Tablet
- Where
- Tanzania
- Volunteers
- 298 people
- Sponsor
- Martin Rohacek
Heart Failure
A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
The purpose of this open-label study was to collect additional safety information of sacubitril/valsartan and to provide post-trial access to sacubitril/valsartan for the eligible Japanese patients who completed…
- Trial name
- NCT06149104
- Testing
- sacubitril/valsartan
- Where
- 6 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
The purpose of the study is to evaluate the efficacy and safety of QR12000 75mg, QR12000 150mg and Sacubitril/valsartan 200mg in patients with moderate to severe essential hypertension.
- Trial name
- NCT06716970
- Testing
- QR12000 75mg, QR12000 150mg, Sacubitril/valsartan 200mg
- Where
- China
- Volunteers
- 810 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Heart Failure
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
This study was to determine early and more chronic changes in concentrations of biomarkers related to mechanisms of action (MOA) and effects of sacubitril/valsartan therapy over a period of 12 months, and correlated these…
- Trial name
- PROVE-HF (NCT02887183)
- Testing
- LCZ696 (sacubitril/valsartan)
- Where
- 77 sites in United States
- Volunteers
- 794 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Effects of Sacubitril/Valsartan on Exercise Capacity, Natriuretic Peptides and Ventricular Remodeling in Heart Failure
Background: Sacubitril/valsartan, a novel therapy in the treatment of heart failure with reduced ejection fraction (HFrEF), has recently proved efficacy in improving exercise tolerance and cardiac performance.
- Trial name
- NCT04434170
- Testing
- Sacubitril-Valsartan
- Where
- Italy
- Volunteers
- 112 people
- Sponsor
- Centro Cardiologico Monzino
Heart Failure With Reduced Ejection Fraction
The ENVI Study: Effect of Entresto on Left Ventricular Remodelling on Cardiac MRI
A prospective, single centre, observational cohort study at University Hospital Southampton NHS Foundation Trust of 50 consecutive patients with Heart Failure with reduced Ejection Fraction and Ejection Fraction ≤35% who are…
- Trial name
- ENVI (NCT05348226)
- Testing
- Additional Cardiac Magnetic Resonance Scan
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Heart Failure
Prospective Observational Study of the Sacubitril-Valsartan Treatment Effectiveness.
The aim of this prospective study is to demonstrate if there is any difference in the treatment response to Sacubitril-Valsartan depending on the ventricular disfunction ethiology in patients with severe systolic disfunction…
- Trial name
- NCT04133428
- Testing
- Sacubitril-Valsartan
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
STEMI
The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction
The primary objective of the PERI-STEMI trial is to assess whether sacubitril-valsartan is more effective in preventing adverse LV remodeling for patients with ST-elevation myocardial infarction (STEMI) than enalapril.
- Trial name
- PERI-STEMI (NCT04912167)
- Testing
- Sacubitril-Valsartan, Enalapril, Valsartan
- Where
- China
- Volunteers
- 376 people
- Sponsor
- West China Hospital
Chronic Heart Failure
LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction
The study will assess the effects of 36 weeks of treatment with LCZ696 compared to valsartan on N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) in patients with chronic heart failure and preserved left-ventricular ejection…
- Trial name
- NCT00887588
- Testing
- LCZ696, Valsartan
- Where
- 81 sites in United States, Argentina and 12 more
- Volunteers
- 307 people
- Sponsor
- Novartis Pharmaceuticals
Congenital Heart Disease, Heart Failure
" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
The treatment of adult patients with congenital heart disease (ACHD) and heart failure (HF) represents a great challenge since, to date, there is no standardized guideline for this specific population.
- Conditions
- Congenital Heart Disease, Heart Failure, Heart Failure With Reduced Ejection Fraction
- Trial name
- NCT05580510
- Testing
- Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID, Empagliflozin 10 MG OD
- Where
- Mexico
- Volunteers
- 160 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Heart Failure With Reduced Ejection Fraction
Changes in Intrathoracic Impedance During Sacubitril/Valsartan Treatment
The CHILISALT Study aimed to explore the effect of angiotensin-neprilysin inhibition on intrathoracic impedance and -derived fluid index in HFrEF patients who had a device for cardiac resynchronization therapy and/or an…
- Trial name
- CHILISALT (NCT03359967)
- Testing
- Entresto tablet
- Volunteers
- 24 people
- Sponsor
- Central Hospital, Izmir
Breast Cancer, Neoplasm, Breast
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more than 2.25 million new cases of breast cancer in women in 2020.
- Conditions
- Breast Cancer, Neoplasm, Breast, Breast Diseases, Antihypertensive Agents
- Trial name
- NCT05465031
- Testing
- Sacubitril-valsartan
- Where
- 4 sites in Poland
- Volunteers
- 600 people
- Sponsor
- Silesian Centre for Heart Diseases
Heart Failure, Ventricular Remodeling
Effects of the Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan Therapy in Patients With HFrEF.
The goal of this observational study is to investigate the effects of combination therapy with ARNI and inhibitors of SGLT2 in patients affected by HFrEF.
- Conditions
- Heart Failure, Ventricular Remodeling, Ventricular Dysfunction
- Trial name
- NCT05934071
- Testing
- SGLT2 inhibitor
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS